Fujairah's new Dh843m Sheikh Khalifa Hospital to boost emirate's health sector
The 222-bed Sheikh Khalifa Hospital was inaugurated by Sheikh Hamad bin Mohammed Al Sharqi, Ruler of Fujairah, and Sheikh Mansour bin Zayed, Vice President, Deputy Prime Minister and Chairman of the Presidential Court, on Tuesday. The state-of-the-art facility was established as part of the UAE President's Initiatives, a nationwide strategy providing essential funding for vital infrastructure projects that serve the public.
The hospital spans 89,000 square metres and has the scope to expand its existing capacity to more than 350 beds. The Fujairah Ruler and Sheikh Mansour, accompanied by several officials, were given a tour of the hospital's extensive facilities, including centres of excellence, operating theatres, intensive care units, laboratories and inpatient wards.
It features three dedicated medical centres of excellence, specialising in burns treatment, rehabilitation and trauma treatment, all equipped with cutting-edge technology to enhance services to patients.
Sheikh Hamad stressed the importance of the new hospital in bolstering the emirate's health sector and enhancing the care delivered to patients. Sheikh Mansour said the hospital was one of the most important projects completed under the President's Initiatives programme.
He said the hospital is central to a broader push to improve healthcare infrastructure across the Emirates. The hospital has high-tech features, including advanced imaging systems such as CT scans, MRI, and tomography, in addition to modern laboratories and specialised equipment for its three centres of excellence.
It also has a modern emergency and trauma department with 30 beds, expandable to 60, and 55 outpatient clinics catering to diverse healthcare needs. Its rehabilitation centre features the latest therapeutic equipment, including speech therapy and audiometry, a hydrotherapy pool, two hyperbaric oxygen therapy rooms and advanced prosthetic support.
The burns unit is comprises 10 patient rooms, five intensive care beds dedicated to burns, and an operating theatre equipped for such cases. The hospital also includes four royal suites, eight VIP suites, 45 beds across medical and surgical wings, 15 general intensive care beds and 10 cardiac ICU beds.
The hospital is managed by The Medical Office (TMO) under PureHealth Group, which oversees the Sheikh Khalifa hospital network in the Northern Emirates, under the umbrella of the President's Initiatives and in co-ordination with the Presidential Court.
It operates 24 hours a day, seven days a week, for emergency and inpatient services. Outpatient clinics receive patients from 8am to 5pm, Monday to Friday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
3 hours ago
- Khaleej Times
GS1 UAE celebrates 25 years of enabling trust, transparency, and innovation
GS1 has marked 25 years of its presence in the UAE – empowering businesses and government entities with globally trusted standards that drive transparency, efficiency, and safety across supply chains. The milestone celebration coincides closely with a historic moment in global commerce today: in June of 1974, the very first product was scanned using a GS1 barcode in a supermarket in Ohio, USA. What began as a simple scan of a pack of chewing gum sparked a revolution in how the world tracks, sells, and understands products. Today, GS1 UAE stands at the forefront of that same legacy — helping businesses in the UAE digitize, standardize, and future-proof their operations. Since its establishment in 2000 in the United Arab Emirates, GS1 UAE has played a pivotal role in the UAE's digital transformation journey. Its globally recognized barcoding, data and traceability standards have become the backbone of key sectors as diverse as retail, healthcare, logistics, manufacturing, and e-commerce. Over the years, GS1 UAE has established strategic collaborations with several key government bodies, including the Federal Tax Authority (FTA), where its standards have been instrumental in enabling excise tax compliance and the traceability of Digital Tax Stamps. GS1 UAE has also supported the Ministry of Health and Prevention (MoHAP) through initiatives like Tatmeen that ensure the authentication of medical products, helping safeguard public health and align with national pharmaceutical safety goals. In the healthcare sector, GS1 UAE has partnered with health authorities such as Dubai Health, Emirates Drug Establishment, and Emirates Health Services, as well as hospitals such as Cleveland Clinic Abu Dhabi, and manufacturer associations such as Mecomed and Pharmag to implement serialization and traceability systems that strengthen patient safety, combat counterfeiting for pharmaceuticals and facilitate unique identification for medical devices. GS1's barcoding solutions in the retail and e-commerce industries have improved inventory accuracy, pricing consistency, and consumer trust, in collaboration with the likes of Dubai Duty Free, Al Ghurair, Transmed, Huda Beauty, Jumbo Electronics, Barakat, and Al Douri, to name a few. 'As we mark this important milestone, we reflect not only on our impact in the private sector but also on the strong partnerships we've built with UAE government institutions to promote trust and transparency at scale,' said Rami Habbal, CEO of GS1 UAE. 'From healthcare safety and regulatory compliance to consumer transparency and sustainability, GS1 UAE remains committed to delivering globally trusted standards that help the UAE lead in innovation.' Looking to the future, GS1 UAE is aligned with the global transition to next-generation QR codes powered by GS1 that will unlock richer trusted data at the point of sale. These QR codes will empower consumers, support sustainability efforts, and enhance real-time supply chain insights.
The National
5 hours ago
- The National
Fujairah's new Dh843m Sheikh Khalifa Hospital to boost emirate's health sector
A new flagship Dh843 million hospital primed to transform patient care in Fujairah has been hailed as one of the country's most advanced healthcare projects. The 222-bed Sheikh Khalifa Hospital was inaugurated by Sheikh Hamad bin Mohammed Al Sharqi, Ruler of Fujairah, and Sheikh Mansour bin Zayed, Vice President, Deputy Prime Minister and Chairman of the Presidential Court, on Tuesday. The state-of-the-art facility was established as part of the UAE President's Initiatives, a nationwide strategy providing essential funding for vital infrastructure projects that serve the public. The hospital spans 89,000 square metres and has the scope to expand its existing capacity to more than 350 beds. The Fujairah Ruler and Sheikh Mansour, accompanied by several officials, were given a tour of the hospital's extensive facilities, including centres of excellence, operating theatres, intensive care units, laboratories and inpatient wards. It features three dedicated medical centres of excellence, specialising in burns treatment, rehabilitation and trauma treatment, all equipped with cutting-edge technology to enhance services to patients. Sheikh Hamad stressed the importance of the new hospital in bolstering the emirate's health sector and enhancing the care delivered to patients. Sheikh Mansour said the hospital was one of the most important projects completed under the President's Initiatives programme. He said the hospital is central to a broader push to improve healthcare infrastructure across the Emirates. The hospital has high-tech features, including advanced imaging systems such as CT scans, MRI, and tomography, in addition to modern laboratories and specialised equipment for its three centres of excellence. It also has a modern emergency and trauma department with 30 beds, expandable to 60, and 55 outpatient clinics catering to diverse healthcare needs. Its rehabilitation centre features the latest therapeutic equipment, including speech therapy and audiometry, a hydrotherapy pool, two hyperbaric oxygen therapy rooms and advanced prosthetic support. The burns unit is comprises 10 patient rooms, five intensive care beds dedicated to burns, and an operating theatre equipped for such cases. The hospital also includes four royal suites, eight VIP suites, 45 beds across medical and surgical wings, 15 general intensive care beds and 10 cardiac ICU beds. The hospital is managed by The Medical Office (TMO) under PureHealth Group, which oversees the Sheikh Khalifa hospital network in the Northern Emirates, under the umbrella of the President's Initiatives and in co-ordination with the Presidential Court. It operates 24 hours a day, seven days a week, for emergency and inpatient services. Outpatient clinics receive patients from 8am to 5pm, Monday to Friday.
Khaleej Times
7 hours ago
- Khaleej Times
UAE becomes first country to approve oral drug for immune thrombocytopenia
The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton's tyrosine kinase (BTK) inhibitor to be authorised in the country for the treatment of Immune Thrombocytopenia (ITP), a rare autoimmune disorder that affects approximately 2 to 5 individuals per 100,000 people worldwide. With this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical needs. The approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of life. The decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatment s in line with the highest international standards and protocols. Developed by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of ITP. By increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.' Dr Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications. 'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.' She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.' For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'
